Sector News

Belgium’s Ablynx triples cooperation deal with Merck & Co

July 22, 2015
Life sciences

(Reuters) – Belgian biotech group Ablynx on Wednesday said it had tripled its research deal with U.S. drugmaker Merck & Co leading to potential milestone payments of about 4 billion euros ($4.38 billion).

Large pharmaceutical groups such as Merck & Co often team up with smaller companies like Ablynx to develop new treatments. A so-called milestone payment is due whenever a programme passes a certain trial phase or clinical tests are successful.

Ablynx, which produces so-called nanobody medicines derived from llama antibodies, said it had expanded its research agreement with Merck & Co by 12 programmes for which it could receive up to 340 million euros each if successful.

The group added it would get a 13 million euro upfront payment for signing the deal expansion. The initial agreement with the U.S. group, signed in February 2014, contained payments of up to 1.7 billion euros. ($1 = 0.9142 euros) (Reporting by Robert-Jan Bartunek; Editing by Anand Basu)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”